VENMAX
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Venmax Drugs&Pharma do?
Venmax Drugs and Pharmaceuticals Limited engages in the manufacture and sale of bulk drugs intermediates primarily in India. It primarily offers trityl chloride. The company, formerly known as Yenkey Drugs and Pharmaceuticals Limited, was incorporated in 1988 and is based in Hyderabad, India.
Who are the competitors of Venmax Drugs&Pharma?
Venmax Drugs&Pharma major competitors are Decipher Labs, Unjha Formulations, Hind Bio Science, Cian Healthcare, Parmax Pharma, Beryl Drugs, iStreet Network. Market Cap of Venmax Drugs&Pharma is ₹12 Crs. While the median market cap of its peers are ₹10 Crs.
Is Venmax Drugs&Pharma financially stable compared to its competitors?
Venmax Drugs&Pharma seems to be less financially stable compared to its competitors. Altman Z score of Venmax Drugs&Pharma is -116.57 and is ranked 8 out of its 8 competitors.
Does Venmax Drugs&Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Venmax Drugs&Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Venmax Drugs&Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Venmax Drugs&Pharma balance sheet?
Venmax Drugs&Pharma balance sheet is weak and might have solvency issues
Is the profitablity of Venmax Drugs&Pharma improving?
No, profit is decreasing. The profit of Venmax Drugs&Pharma is ₹0.06 Crs for Mar 2024, ₹0.23 Crs for Mar 2023 and ₹1.85 Crs for Mar 2022
Is the debt of Venmax Drugs&Pharma increasing or decreasing?
The net debt of Venmax Drugs&Pharma is decreasing. Latest net debt of Venmax Drugs&Pharma is -₹2.43 Crs as of Mar-25. This is less than Mar-24 when it was ₹0.35 Crs.
Is Venmax Drugs&Pharma stock expensive?
There is insufficient historical data to gauge this. Latest PE of Venmax Drugs&Pharma is -1209.67
Has the share price of Venmax Drugs&Pharma grown faster than its competition?
Venmax Drugs&Pharma has given better returns compared to its competitors. Venmax Drugs&Pharma has grown at ~34.16% over the last 6yrs while peers have grown at a median rate of 15.23%
Is the promoter bullish about Venmax Drugs&Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Venmax Drugs&Pharma is 23.13% and last quarter promoter holding is 23.13%.
Are mutual funds buying/selling Venmax Drugs&Pharma?
There is Insufficient data to gauge this.